2021-09-07

Department of Psychology, Southwest University, Chongqing, China.; Department of Psychology, Southwest University, Chongqing, China.; Department of Medcine, Yan'an University, Yan'an, China.; Department of Psychology, Southwest University, Chongqing, China.; Department of Psychology, Southwest University, Chongqing, China.

Background: The novel 2019 coronavirus disease (COVID-19) pandemic has spread rapidly worldwide and poses a global health threat. Aims: This study assessed the prevalence of anxiety and depression symptoms in Chinese students during the COVID-19 pandemic and explored potential moderating factors. Methods: We searched English and Chinese databases using pertinent keywords for articles published and unpublished, up until November 2020. The estimate of the overall prevalence of anxiety and depression was conducted through a random-effects model. Results: A total of 31 cross-sectional studies were included. The overall prevalence of anxiety and depression symptoms in Chinese students during the COVID-19 pandemic was 24.0% (95% CI [20.0-29.0%]) and 22.0% (95% CI [18.0-27.0%]) respectively. Subgroup analyses revealed that Chinese middle school students were at heightened risk of anxiety, while university students were at heightened risk of depression. Students who lived in higher-risk areas

2021-04-05

Department of Infectious Diseases, Beijing You an Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing, 100069, People's Republic of China.; Department of Infectious Diseases, Beijing You an Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing, 100069, People's Republic of China.; Department of Infectious Diseases, Beijing You an Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing, 100069, People's Republic of China.; Department of Infectious Diseases, Beijing You an Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing, 100069, People's Republic of China.; Department of Respiratory and Infectious Diseases, Beijing You an Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing, 100069, People's Republic of China.

Severe acute respiratory syndrome coronavirus clade 2 (SARS-CoV-2) is an emerging pathogen, which is similar to previous SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) occurrences. However, we only get few understandings about the pathogenesis of SARS-CoV-2, which need to further be studied. The discovery of an agent that has a treatment efficacy against SARS-CoV-2 is very urgent. In this review, we briefly discuss the virology of this pathogen and focus on the available understanding of the pathogenesis and treatments of this pathogen including the uses of nucleoside analogues, protease inhibitors, interferons, and other small-molecule drugs, on the basis previous comprehensions of SARS and MERS. These reviewed concepts may be beneficial in providing new insights and potential treatments for COVID-19.CI - © 2021 Yang et al.

2021-08-02

Center for Infection and Immunity, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong, China.; School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, China.; Guangdong Provincial Engineering Research Center of Molecular Imaging, Guangdong Provincial Key Laboratory of Biomedical Imaging, and Department of Interventional Medicine, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong, China.; Southern Marine Science and Engineering Guangdong Laboratory, Zhuhai, Guangdong, China.; National Clinical Research Center for Infectious Disease, Shenzhen Third People' s Hospital; The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong, China.; School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, China.; Center for Infection and Immunity, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong, China.; Guangdong Provincial Engineering Research Center of Molecular Imaging, Guangdong Provincial Key Laboratory of Biomedical Imaging, and Department of Interventional Medicine, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong, China.; Department of Clinical Laboratory, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China.; Center for Infection and Immunity, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong, China.; Guangdong Provincial Engineering Research Center of Molecular Imaging, Guangdong Provincial Key Laboratory of Biomedical Imaging, and Department of Interventional Medicine, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong, China.; Center for Infection and Immunity, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong, China.; Guangdong Provincial Engineering Research Center of Molecular Imaging, Guangdong Provincial Key Laboratory of Biomedical Imaging, and Department of Interventional Medicine, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong, China.; National Clinical Research Center for Infectious Disease, Shenzhen Third People' s Hospital; The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong, China.; Center for Infection and Immunity, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong, China.; Guangdong Provincial Engineering Research Center of Molecular Imaging, Guangdong Provincial Key Laboratory of Biomedical Imaging, and Department of Interventional Medicine, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong, China.; School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, China. lujiahai@mail.sysu.edu.cn.; Center for Infection and Immunity, Mailman School of Public Health, Columbia University, New York, NY, USA. cg2984@cumc.columbia.edu.; Guangdong Provincial Engineering Research Center of Molecular Imaging, Guangdong Provincial Key Laboratory of Biomedical Imaging, and Department of Interventional Medicine, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong, China. shanhong@mail.sysu.edu.cn.; Southern Marine Science and Engineering Guangdong Laboratory, Zhuhai, Guangdong, China. shanhong@mail.sysu.edu.cn.; Center for Infection and Immunity, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong, China. huangxi6@mail.sysu.edu.cn.; Guangdong Provincial Engineering Research Center of Molecular Imaging, Guangdong Provincial Key Laboratory of Biomedical Imaging, and Department of Interventional Medicine, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong, China. huangxi6@mail.sysu.edu.cn.; Southern Marine Science and Engineering Guangdong Laboratory, Zhuhai, Guangdong, China. huangxi6@mail.sysu.edu.cn.; National Clinical Research Center for Infectious Disease, Shenzhen Third People' s Hospital; The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong, China. huangxi6@mail.sysu.edu.cn.

The human oral and gut commensal microbes play vital roles in the development and maintenance of immune homeostasis, while its association with susceptibility and severity of SARS-CoV-2 infection is barely understood. In this study, we investigated the dynamics of the oral and intestinal flora before and after the clearance of SARS-CoV-2 in 53 COVID-19 patients, and then examined their microbiome alterations in comparison to 76 healthy individuals. A total of 140 throat swab samples and 81 fecal samples from these COVID-19 patients during hospitalization, and 44 throat swab samples and 32 fecal samples from sex and age-matched healthy individuals were collected and then subjected to 16S rRNA sequencing and viral load inspection. We found that SARS-CoV-2 infection was associated with alterations of the microbiome community in patients as indicated by both alpha and beta diversity indexes. Several bacterial taxa were identified related to SARS-CoV-2 infection, wherein elevated

2021-03-24

The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine.; Neck-Shoulder and Lumbocrural Pain Hospital Affiliated to Shandong First Medical University, Jinan.; The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine.; The Second Clinical Medical College of Shandong University of Traditional Chinese Medicine.; Rizhao Hospital of Traditional Chinese Medicine.; The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine.; The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine.; The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine.; The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine.; School of Rehabilitation Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.

BACKGROUND: Since the outbreak of coronavirus disease 2019 (COVID-19), with the improvement of diagnosis and treatment level in various countries, more and more patients have been discharged after systematic treatment. In order to effectively promote the overall recovery of patients' physical and mental function and quality of life (QOL), the focus of clinical work should be gradually shifted to rehabilitation treatment. Dance-based mind-motor activities were defined as coordinated upright mind-motor movements that emphasize dynamic balance, structured through music or an inner rhythm (e.g., breathing) and distinctive instructions or choreography, and that involve social interaction. It has positive effects on motor function, lung function, psychological mood and other aspects, so it can be used as a safe alternative therapy for patients recovering from COVID-19. At present, there are no relevant articles for systematic review. METHODS: From its inception until March 2021, we will

Division of Rheumatology, Department of Medicine, Columbia University Irving Medical Center, 161 Fort Washington Avenue, 2nd Floor, New York, NY, 10032, USA.; Division of Rheumatology, Department of Medicine, Columbia University Irving Medical Center, 161 Fort Washington Avenue, 2nd Floor, New York, NY, 10032, USA.; Division of Rheumatology, Department of Medicine, Columbia University Irving Medical Center, 161 Fort Washington Avenue, 2nd Floor, New York, NY, 10032, USA.; Division of Rheumatology, Department of Medicine, Columbia University Irving Medical Center, 161 Fort Washington Avenue, 2nd Floor, New York, NY, 10032, USA.; Division of Rheumatology, Department of Medicine, Columbia University Irving Medical Center, 161 Fort Washington Avenue, 2nd Floor, New York, NY, 10032, USA.; Division of Rheumatology, Department of Medicine, Columbia University Irving Medical Center, 161 Fort Washington Avenue, 2nd Floor, New York, NY, 10032, USA.; Division of Rheumatology, Department of Medicine, Columbia University Irving Medical Center, 161 Fort Washington Avenue, 2nd Floor, New York, NY, 10032, USA.; Division of Infectious Disease, Department of Medicine, Columbia University Irving Medical Center, New York, NY, 10032, USA.; Division of Rheumatology, Department of Medicine, Columbia University Irving Medical Center, 161 Fort Washington Avenue, 2nd Floor, New York, NY, 10032, USA. ada20@cumc.columbia.edu.

Since the first outbreak of Coronavirus Disease-2019 (COVID-19) in January 2020, the medical community has been pursuing effective countermeasures. Early in the pandemic, several small clinical and in vitro studies from France and China reported on the efficacy of chloroquine (CQ) and hydroxychloroquine (HCQ) against SARS-CoV-2 infections, which generated global attention towards these decades-old antimalarials (AM) and heralded numerous studies investigating their role in treating COVID-19. Despite several observational studies early in the pandemic affirming their beneficial role in treating COVID-19, 12 clinical studies reported no mortality benefits for CQ/HCQ in COVID-19 patients. The excitement over CQ/HCQ was ultimately quenched after three large randomized clinical trials, the COALITION-I trial in Brazil, the RECOVERY trial in the United Kingdom (UK), and the SOLIDARITY trial from World Health Organization (WHO) consistently reported no beneficial effects for CQ/HCQ in

2021-12-07

National Clinical Research Center for Infectious Disease, Institute for Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China.; National Clinical Research Center for Infectious Disease, Institute for Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China.; Department for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, China.; National Clinical Research Center for Infectious Disease, Institute for Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China.; National Clinical Research Center for Infectious Disease, Institute for Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China.; Department for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, China.; Guangdong Province Research & Development Centre of Protein (Peptide) Separation Engineering Technology, Shenzhen, China.; Guangdong Province Research & Development Centre of Protein (Peptide) Separation Engineering Technology, Shenzhen, China.; Guangdong Province Research & Development Centre of Protein (Peptide) Separation Engineering Technology, Shenzhen, China.; Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.; National Clinical Research Center for Infectious Disease, Institute for Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China.; Shenzhen Research Center for Communicable Disease Diagnosis and Treatment of Chinese Academy of Medical Science, Shenzhen, Guangdong Province, China.; National Clinical Research Center for Infectious Disease, Institute for Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China.; Shenzhen Research Center for Communicable Disease Diagnosis and Treatment of Chinese Academy of Medical Science, Shenzhen, Guangdong Province, China.; Shenzhen Bay Laboratory, Shenzhen, Guangdong Province, China.

2021-10-17

Department of Oncology, The First Affiliated Hospital of USTC, Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, 230021 Hefei, Anhui, China; CAS Center for Excellence in Molecular Cell Sciences, the CAS Key Laboratory of Innate Immunity and Chronic Disease, University of Science and Technology of China, 230027 Hefei, Anhui, China.; Department of Oncology, The First Affiliated Hospital of USTC, Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, 230021 Hefei, Anhui, China; CAS Center for Excellence in Molecular Cell Sciences, the CAS Key Laboratory of Innate Immunity and Chronic Disease, University of Science and Technology of China, 230027 Hefei, Anhui, China.; Department of Oncology, The First Affiliated Hospital of USTC, Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, 230021 Hefei, Anhui, China; CAS Center for Excellence in Molecular Cell Sciences, the CAS Key Laboratory of Innate Immunity and Chronic Disease, University of Science and Technology of China, 230027 Hefei, Anhui, China.; Department of Oncology, The First Affiliated Hospital of USTC, Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, 230021 Hefei, Anhui, China; School of Data Science, University of Science and Technology of China, 230026 Hefei, Anhui, China.; Department of Oncology, The First Affiliated Hospital of USTC, Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, 230021 Hefei, Anhui, China.; Department of Oncology, The First Affiliated Hospital of USTC, Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, 230021 Hefei, Anhui, China.; Department of Oncology, The First Affiliated Hospital of USTC, Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, 230021 Hefei, Anhui, China; School of Life Science and Technology, University of Electronic Science and Technology of China, 610054 Chengdu, Sichuan, China.; Department of Oncology, The First Affiliated Hospital of USTC, Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, 230021 Hefei, Anhui, China; Institute for Advanced Study, Nanchang University, 330031 Nanchang, Jiangxi, China.; Department of Oncology, The First Affiliated Hospital of USTC, Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, 230021 Hefei, Anhui, China.; Department of Oncology, The First Affiliated Hospital of USTC, Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, 230021 Hefei, Anhui, China.; Department of Oncology, The First Affiliated Hospital of USTC, Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, 230021 Hefei, Anhui, China; HanGene Biotech, Xiaoshan Innovation Polis, 31200 Hangzhou, Zhejiang, China.; Department of Oncology, The First Affiliated Hospital of USTC, Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, 230021 Hefei, Anhui, China; CAS Center for Excellence in Molecular Cell Sciences, the CAS Key Laboratory of Innate Immunity and Chronic Disease, University of Science and Technology of China, 230027 Hefei, Anhui, China.; Department of Oncology, The First Affiliated Hospital of USTC, Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, 230021 Hefei, Anhui, China. Electronic address: gchuang@ustc.edu.cn.; Department of Oncology, The First Affiliated Hospital of USTC, Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, 230021 Hefei, Anhui, China; CAS Center for Excellence in Molecular Cell Sciences, the CAS Key Laboratory of Innate Immunity and Chronic Disease, University of Science and Technology of China, 230027 Hefei, Anhui, China; School of Data Science, University of Science and Technology of China, 230026 Hefei, Anhui, China. Electronic address: qukun@ustc.edu.cn.

The mortality risk of coronavirus disease 2019 (COVID-19) patients has been linked to the cytokine storm caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Understanding the inflammatory responses shared between COVID-19 and other infectious diseases that feature cytokine storms may therefore help in developing improved therapeutic strategies. Here, we use integrative analysis of single-cell transcriptomes to characterize the inflammatory signatures of peripheral blood mononuclear cells from patients with COVID-19, sepsis, and HIV infection. We identify ten hyperinflammatory cell subtypes in which monocytes are the main contributors to the transcriptional differences in these infections. Monocytes from COVID-19 patients share hyperinflammatory signatures with HIV infection and immunosuppressive signatures with sepsis. Finally, we construct a "three-stage" model of heterogeneity among COVID-19 patients, related to the hyperinflammatory and immunosuppressive

2021-03-08

Department of Critical Care Medicine, The People's Hospital of China Three Gorges University, The First People's Hospital of Yichang.; Department of Critical Care Medicine, The People's Hospital of China Three Gorges University, The First People's Hospital of Yichang.; Department of Pulmonary and Critical Care Medicine, The Third People's Hospital of Yichang, China Three Gorges University Third People's Hospital.; Department of Critical Care Medicine, The People's Hospital of China Three Gorges University, The First People's Hospital of Yichang.; Department of Pulmonary and Critical Care Medicine, The Third People's Hospital of Yichang, China Three Gorges University Third People's Hospital.; Medical Department, The People's Hospital of China Three Gorges University, The First People's Hospital of Yichang, Yichang, Hubei, China.; Department of Critical Care Medicine, The People's Hospital of China Three Gorges University, The First People's Hospital of Yichang.; Department of Critical Care Medicine, The People's Hospital of China Three Gorges University, The First People's Hospital of Yichang.; Department of Critical Care Medicine, The People's Hospital of China Three Gorges University, The First People's Hospital of Yichang.; Department of Critical Care Medicine, The People's Hospital of China Three Gorges University, The First People's Hospital of Yichang.; Department of Critical Care Medicine, The People's Hospital of China Three Gorges University, The First People's Hospital of Yichang.; Department of Critical Care Medicine, The People's Hospital of China Three Gorges University, The First People's Hospital of Yichang.

Mortality of critically ill patients with coronavirus disease 2019 (COVID-19) was high. Aims to examine whether time from symptoms onset to intensive care unit (ICU) admission affects incidence of extra-pulmonary complications and prognosis in order to provide a new insight for reducing the mortality. A single-centered, retrospective, observational study investigated 45 critically ill patients with COVID-19 hospitalized in ICU of The Third People's Hospital of Yichang from January 17 to March 29, 2020. Patients were divided into 2 groups according to time from symptoms onset to ICU admission (>7 and ≤7 days) and into 2 groups according to prognosis (survivors and non-survivors). Epidemiological, clinical, laboratory, radiological characteristics and treatment data were studied. Compared with patients who admitted to the ICU since symptoms onset ≤7 days (55.6%), patients who admitted to the ICU since symptoms onset >7 days (44.4%) were more likely to have extra-pulmonary complications

Department of Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, China.; National Medical Products Administration (NMPA) Key Laboratory for Quality Monitoring and Evaluation of Vaccines and Biological Products, Guangzhou, China.; Center for Infection and Immunity, Mailman School of Public Health, Columbia University, New York, NY, United States.; Futian District Center for Disease Control and Prevention, Shenzhen, China.; Department of Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, China.; National Medical Products Administration (NMPA) Key Laboratory for Quality Monitoring and Evaluation of Vaccines and Biological Products, Guangzhou, China.; Department of Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, China.; National Medical Products Administration (NMPA) Key Laboratory for Quality Monitoring and Evaluation of Vaccines and Biological Products, Guangzhou, China.; Department of Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, China.; National Medical Products Administration (NMPA) Key Laboratory for Quality Monitoring and Evaluation of Vaccines and Biological Products, Guangzhou, China.; Department of Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, China.; National Medical Products Administration (NMPA) Key Laboratory for Quality Monitoring and Evaluation of Vaccines and Biological Products, Guangzhou, China.; Department of Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, China.; National Medical Products Administration (NMPA) Key Laboratory for Quality Monitoring and Evaluation of Vaccines and Biological Products, Guangzhou, China.; Department of Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, China.; National Medical Products Administration (NMPA) Key Laboratory for Quality Monitoring and Evaluation of Vaccines and Biological Products, Guangzhou, China.; Laboratory Animal Center, Sun Yat-sen University, Guangzhou, China.; Department of Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, China.; National Medical Products Administration (NMPA) Key Laboratory for Quality Monitoring and Evaluation of Vaccines and Biological Products, Guangzhou, China.; Department of Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, China.; National Medical Products Administration (NMPA) Key Laboratory for Quality Monitoring and Evaluation of Vaccines and Biological Products, Guangzhou, China.

Recent exposure to seasonal coronaviruses (sCoVs) may stimulate cross-reactive antibody responses against severe acute respiratory syndrome CoV 2 (SARS-CoV-2). However, previous studies have produced divergent results regarding protective or damaging immunity induced by prior sCoV exposure. It remains unknown whether pre-existing humoral immunity plays a role in vaccine-induced neutralization and antibody responses. In this study, we collected 36 paired sera samples from 36 healthy volunteers before and after immunization with inactivated whole-virion SARS-CoV-2 vaccines for COVID-19, and analyzed the distribution and intensity of pre-existing antibody responses at the epitope level pre-vaccination as well as the relationship between pre-existing sCoV immunity and vaccine-induced neutralization. We observed large amounts of pre-existing cross-reactive antibodies in the conserved regions among sCoVs, especially the S2 subunit. Excep t for a few peptides, the IgG and IgM fluorescence

2021-05-10

Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China jialiu77@hust.edu.cn bjwang73@163.com.; Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Wuhan, China.; Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Wuhan, China.; Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Wuhan, China.; Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Wuhan, China.; Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Wuhan, China.; Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Wuhan, China.; Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Wuhan, China.; Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Wuhan, China.; Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Institute for Virology, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany.; Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Wuhan, China.; Institute for Virology, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany.; Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Wuhan, China.; Institute for Virology, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany.; Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Wuhan, China.; Institute for Virology, Heinrich-Heine-University, University Hospital, Duesseldorf, Germany.; Institute for Virology, Heinrich-Heine-University, University Hospital, Duesseldorf, Germany.; Institute for Virology, Heinrich-Heine-University, University Hospital, Duesseldorf, Germany.; Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.; Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.; Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Wuhan, China.; Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Wuhan, China.; Institute for Virology, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany.; Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Wuhan, China.; Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Wuhan, China.; Institute for Virology, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany.; Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Wuhan, China.; Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China jialiu77@hust.edu.cn bjwang73@163.com.; Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Wuhan, China.; Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Wuhan, China.

The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) affected over 120 million people and killed over 2.7 million individuals by March 2021. While acute and intermediate interactions between SARS-CoV-2 and the immune system have been studied extensively, long-term impacts on the cellular immune system remain to be analyzed. Here, we comprehensively characterized immunological changes in peripheral blood mononuclear cells in 49 COVID-19-convalescent individuals (CI) in comparison to 27 matched SARS-CoV-2-unexposed individuals (UI). Despite recovery from the disease for more than 2 months, CI showed significant decreases in frequencies of invariant NKT and NKT-like cells compared to UI. Concomitant with the decrease in NKT-like cells, an increase in the percentage of annexin V and 7-aminoactinomycin D (7-AAD) double-positive NKT-like cells was detected, suggesting that the reduction in NKT-like cells results from